KeyBanc Initiates Standard BioTools at Overweight With $4 Price Target, Sees 'Attractively Valued Way to Invest' in Life Sciences Technology
KeyBanc Initiates Standard BioTools at Overweight With $4 Price Target, Sees 'Attractively Valued Way to Invest' in Life Sciences Technology
KeyBanc以增持方式啓動標準BioTools，目標股價爲4美元，認爲生命科學技術是 “具有吸引力的投資方式”
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊